Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Amgen Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 10,944 34,741 34,248 31,560 7,629 9,502 5,203 6,528 7,989 11,969 6,630 6,112 6,266 9,087 9,145 7,687 6,037 11,415 5,525 7,358
Marketable securities 1 1,676 1,976 1,980 16 48 952 1,452 4,454 4,381 3,273 2,276 325 2,874 9,438 16,233 18,943
Trade receivables, net 7,268 6,145 5,830 5,736 5,563 5,326 5,327 5,077 4,895 4,765 4,479 4,423 4,525 4,094 5,366 5,009 4,057 3,606 3,801 3,771
Inventories 9,518 5,026 4,978 5,011 4,930 4,757 4,554 4,411 4,086 4,152 4,115 4,017 3,893 3,942 3,840 3,682 3,584 3,243 3,176 3,016
Other current assets 2,602 2,565 2,324 2,395 2,388 2,501 2,258 2,488 2,367 2,542 2,423 2,293 2,079 2,265 2,268 2,110 1,888 3,349 2,011 2,063
Current assets 30,332 48,477 47,380 44,703 22,186 24,062 19,322 18,520 19,385 24,380 19,099 21,299 21,144 22,661 22,895 18,813 18,440 31,051 30,746 35,151
Property, plant and equipment, net 5,941 5,563 5,532 5,460 5,427 5,188 5,158 5,142 5,184 4,982 4,906 4,855 4,889 4,816 4,843 4,879 4,928 4,901 4,882 4,892
Intangible assets, net 32,641 13,150 14,633 15,393 16,080 13,266 13,927 14,567 15,182 14,659 15,308 15,947 16,587 17,254 17,948 18,653 19,413 6,702 6,813 7,124
Goodwill 18,629 15,509 15,531 15,531 15,529 14,845 14,865 14,897 14,890 14,665 14,676 14,673 14,689 14,674 14,678 14,683 14,703 14,705 14,689 14,692
Other noncurrent assets 9,611 7,835 7,193 7,633 5,899 6,339 6,022 6,070 6,524 6,307 5,784 5,765 5,639 5,232 4,647 4,641 2,223 2,176 2,243 2,138
Noncurrent assets 66,822 42,057 42,889 44,017 42,935 39,638 39,972 40,676 41,780 40,613 40,674 41,240 41,804 41,976 42,116 42,856 41,267 28,484 28,627 28,846
Total assets 97,154 90,534 90,269 88,720 65,121 63,700 59,294 59,196 61,165 64,993 59,773 62,539 62,948 64,637 65,011 61,669 59,707 59,535 59,373 63,997

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Amgen Inc. current assets increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Amgen Inc. property, plant and equipment, net increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amgen Inc. noncurrent assets decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Amgen Inc. total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Amgen Inc. cash and cash equivalents increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Marketable securities Amount of investment in marketable security, classified as current.
Trade receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Amgen Inc. trade receivables, net increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Amgen Inc. inventories increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.